*Refresh the page if the below document does not appear.
Natco Pharma Limited has announced the launch of the first generic version of Pomalyst (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market, through their commercial partner Juno Pharmaceuticals Pvt. Ltd.
Due to the new U.S drug pricing law enacted in August, major drug-making firms described significant uncertainty over how the law will be implemented and how it might directly affect their business.
The firm announced its consolidated results for the Second Quarter (Q2) and Half Year (H1) that ended 30th September 2022. It reported a year-on-year loss for that Quarter. On the other hand, the revenue grew by 11 percent to INR 3,202 Crore.
On Tuesday, the company cut down its full-year revenue forecast for the second time in three months followed by a reduced global supply and decreasing demand of the COVID-19 Vaccine.
The Mumbai-based drug-making company has signed a pact with SPARC (Sun Pharma Advanced Research Company) to commercialize benzyl alcohol and propylene glycol-free phenobarbital sodium powder for injection in the US market.
The Subject Expert Committee under the country’s drug regulatory organization has informed Emcure Pharma to conduct a PK study and phase III trial in the Indian population before they decide for the marketing of its glaucoma drug Acetazolamide for injection (USP 500 mg).
If you don’t already have an account click the button below to create your account.Create New Account